Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Merlini

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
JAMA Network Open|January 24, 2025
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal TumorsMaria Concetta Nigro, Andrea Marchetti, Elena Rosa Fumagalli, et al.
International Journal of Molecular Sciences|September 23, 2022
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GISTErika Fiorino, Alessandra Merlini, Lorenzo D'Ambrosio, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2020
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma HistotypesValeria Leuci, Chiara Donini, Giovanni Grignani, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 6, 2024
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancerMuhlis Akman, Ciro Monteleone, Gabriella Doronzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 SuppressionSilvia Stacchiotti, Silvia Martini, Sandro Pasquali, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 23, 2023
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanomaLidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, et al.
JAMA Network Open|November 6, 2023
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma GroupLorenzo D'Ambrosio, Elena Fumagalli, Tommaso Martino De Pas, et al.
Journal of Translational Medicine|March 11, 2026
Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinomaFrancesca Jacobs, Lorenzo Manganaro, Lorenzo D'Ambrosio, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
JAMA Network Open|January 24, 2025
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal TumorsMaria Concetta Nigro, Andrea Marchetti, Elena Rosa Fumagalli, et al.
International Journal of Molecular Sciences|September 23, 2022
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GISTErika Fiorino, Alessandra Merlini, Lorenzo D'Ambrosio, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2020
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma HistotypesValeria Leuci, Chiara Donini, Giovanni Grignani, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 6, 2024
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancerMuhlis Akman, Ciro Monteleone, Gabriella Doronzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 SuppressionSilvia Stacchiotti, Silvia Martini, Sandro Pasquali, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 23, 2023
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanomaLidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, et al.
JAMA Network Open|November 6, 2023
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma GroupLorenzo D'Ambrosio, Elena Fumagalli, Tommaso Martino De Pas, et al.
Journal of Translational Medicine|March 11, 2026
Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinomaFrancesca Jacobs, Lorenzo Manganaro, Lorenzo D'Ambrosio, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Pageof 5